Overview

Evaluation of the Efficacy and Safety of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Phase:
Phase 2
Details
Lead Sponsor:
LENZ Therapeutics, Inc
Collaborator:
ORA, Inc.
Treatments:
Aceclidine
Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions